天境生物上涨2.57%，报4.995美元/股，总市值5.74亿美元

Core Insights - Tianjing Biological (IMAB) opened with a 2.57% increase on August 18, reaching $4.995 per share, with a total market capitalization of $574 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, an increase of 41.54% year-on-year [1] Company Overview - Tianjing Biological is an offshore holding company registered abroad, operating through its domestic subsidiary Tianjing Biological, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, addressing unmet clinical needs and improving the quality of life for patients worldwide [2] - The mission of the company is to become a leading biopharmaceutical company rooted in China and oriented towards global markets [2]